Unraveling the mysteries of endostatin

IUBMB Life

Volumn 61, Issue 6, 2009, Pages 613-626

  Fu, Yan ^a   Tang, Huadong ^a   Huang, Yujie ^a   Song, Nan ^a   Luo, Yongzhang ^a  

^a TSINGHUA UNIVERSITY   (China)

Author keywords

Clinical trials; Endostatin; Folding criteria; Receptor; Zinc binding

Indexed keywords

CISPLATIN; ENDOSTAR; ENDOSTATIN; NAVELBINE; PLACEBO; RECOMBINANT PROTEIN; UNCLASSIFIED DRUG; YH 16; ZINC ION; ACID; ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; DISULFIDE;

ADVANCED CANCER; AMINO TERMINAL SEQUENCE; ANEMIA; ANTINEOPLASTIC ACTIVITY; CARCINOID; CHEMOTHERAPY INDUCED EMESIS; CIRCULAR DICHROISM; CLINICAL TRIAL; DISULFIDE BOND; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; LEUKOPENIA; LUNG NON SMALL CELL CANCER; NAUSEA; NEUROENDOCRINE TUMOR; NEUTROPENIA; NONHUMAN; NUCLEAR MAGNETIC RESONANCE; PANCREAS TUMOR; POLYACRYLAMIDE GEL ELECTROPHORESIS; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FOLDING; PROTEIN FUNCTION; PROTEIN STABILITY; PROTEIN STRUCTURE; REVIEW; SINGLE DRUG DOSE; SOLID TUMOR; TREATMENT RESPONSE; ANIMAL; CHEMISTRY; CHINA; DRUG EFFECT; ENDOTHELIUM CELL; PHYSIOLOGY; UNITED STATES;

ACIDS; ANGIOGENESIS INHIBITORS; ANIMALS; ANTINEOPLASTIC AGENTS; CHINA; CLINICAL TRIALS AS TOPIC; DISULFIDES; ENDOSTATINS; ENDOTHELIAL CELLS; HUMANS; PROTEIN FOLDING; RECOMBINANT PROTEINS; UNITED STATES;

EID: 69449104191     PISSN: 15216543     EISSN: 15216551     Source Type: Journal    
DOI: 10.1002/iub.215     Document Type: Review

References (94)

1. Dhanabal, M., Ramchandran, R., Volk, R., Stillman, I. E., Lombardo, M., Iruela-Arispe, M. L., Simons, M., and Sukhatme, V. P. (1999) Endostatin: yeast production, mutants, and antitumor effect in renal cell carcinoma. Cancer Res. 59, 189-197. (Pubitemid 29062977)
2. Yamaguchi, N., Anand-Apte, B., Lee, M., Sasaki, T., Fukai, N., Shapiro, R., Que, I., Lowik, C., Timpl, R., and Olsen, B. R. (1999) Endostatin inhibits VEGF-induced endothelial cell migration and tumor growth independently of zinc binding. EMBO J. 18, 4414-4423. (Pubitemid 29391251)
3. O'Reilly, M. S., Boehm, T., Shing, Y., Fukai, N., Vasios, G., Lane, W. S., Flynn, E., Birkhead, J. R., Olsen, B. R., and Folkman, J. (1997) Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell 88, 277-285.
4. Boehm, T., Folkman, J., Browder, T., and O'Reilly, M. S. (1997) Anti-angiogenic therapy of experimental cancer does not induce acquired drug resistance. Nature 390, 404-407.
5. Li, B., Wu, X., Zhou, H., Chen, Q., and Luo, Y. (2004) Acid-induced unfolding mechanism of recombinant human endostatin. Biochemistry 43, 2550-2557.
6. Wu, X., Huang, J., Chang, G., and Luo, Y. (2004) Detection and characterization of an acid-induced folding intermediate of endostatin. Biochem. Biophys. Res. Commun. 320, 973-978.
7. Fu, Y., Wu, X., Han, Q., Liang, Y., He, Y., and Luo, Y. (2007) Sulfate stabilizes the folding intermediate more than the native structure of endostatin. Arch. Biochem. Biophys. 471, 232-239.
8. Zhou, H., Wang, W., and Luo, Y. (2005) Contributions of disulfide bonds in a nested pattern to the structure, stability, and biological functions of endostatin. J. Biol. Chem. 280, 11303-11312.
9. Luo, P. and Baldwin, R. L. (1997) Mechanism of helix induction by tri-fluoroethanol: a framework for extrapolating the helixforming properties of peptides from trifluoroethanol/water mixtures back to water. Biochemistry 36, 8413-8421.
10. Luo, Y. and Baldwin, R. L. (1998) Trifluoroethanol stabilizes the pH 4 folding intermediate of sperm whale apomyoglobin. J. Mol. Biol. 279, 49-57.
11. Dixelius, J., Larsson, H., Sasaki, T., Holmqvist, K., Lu, L., Engstrom, A., Timpl, R., Welsh, M., and Claesson-Welsh, L. (2000) Endostatininduced tyrosine kinase signaling through the Shb adaptor protein regulates endothelial cell apoptosis. Blood 95, 3403-3411.
12. Shi, H., Huang, Y., Zhou, H., Song, X., Yuan, S., Fu, Y., and Luo, Y. (2007) Nucleolin is a receptor that mediates antiangiogenic and antitumor activity of endostatin. Blood 110, 2899-2906.
13. Ding, Y. H., Javaherian, K., Lo, K. M., Chopra, R., Boehm, T., Lanciotti, J., Harris, B. A., Li, Y., Shapiro, R., Hohenester, E., Timpl, R., Folkman, J., and Wiley, D. C. (1998) Zinc-dependent dimers observed in crystals of human endostatin. Proc. Natl. Acad. Sci. USA 95, 10443-10448.
14. Hohenester, E., Sasaki, T., Olsen, B. R., and Timpl, R. (1998) Crystal structure of the angiogenesis inhibitor endostatin at 1.5 A resolution. EMBO J. 17, 1656-1664.
15. Anfinsen, C. B. and Haber, E. (1961) Studies on the reduction and reformation of protein disulfide bonds. J. Biol. Chem. 236, 1361-1363.
16. Pace, C. N., Grimsley, G. R., Thomson, J. A., and Barnett, B. J. (1988) Conformational stability and activity of ribonuclease-T1 with zero, one, and two intact disulfide bonds. J. Biol. Chem. 263, 11820-11825.
17. Morbidelli, L., Donnini, S., Chillemi, F., Giachetti, A., and Ziche, M. (2003) Angiosuppressive and angiostimulatory effects exerted by synthetic partial sequences of endostatin. Clin. Cancer Res. 9, 5358-5369.
18. Deininger, M. H., Fimmen, B. A., Thal, D. R., Schluesener, H. J., and Meyermann, R. (2002) Aberrant neuronal and paracellular deposition of endostatin in brains of patients with Alzheimer's disease. J. Neurosci. 22, 10621-10626.
19. Dringen, R. (2000) Metabolism and functions of glutathione in brain. Prog. Neurobiol. 62, 649-671.
20. He, Y., Zhou, H., Tang, H., and Luo, Y. (2006) Deficiency of disulfide bonds facilitating fibrillogenesis of endostatin. J. Biol. Chem. 281, 1048-1057.
21. Chura-Chambi, R. M., Genova, L. A., Affonso, R., and Morganti, L. (2008) Refolding of endostatin from inclusion bodies using high hydrostatic pressure. Anal. Biochem. 379, 32-39.
22. You, W.-K., So, S.-H., Lee, H., Park, S.-Y., Yoon, M.-R., Chang, S.-I., Kim, H.-K., Joe, Y.-A., Hong, Y.-K., and Chung, S.-I. (1999) Purification and characterization of recombinant murine endostatin in E. coli. Exp. Mol. Med. 31, 197-202.
23. Luo, Y., Kay, M. S., and Baldwin, R. L. (1997) Cooperativity of folding of the apomyoglobin pH 4 intermediate studied by glycine and proline mutations. Nat. Struct. Biol. 4, 925-930.
24. Loh, S. N., Kay, M. S., and Baldwin, R. L. (1995) Structure and stability of a second molten globule intermediate in the apomyoglobin folding pathway. Proc. Natl. Acad. Sci. USA 92, 5446-5450.
25. Redfield, C. and Dobson, C. M. (1988) Sequential 1H NMR assignments and secondary structure of hen egg white lysozyme in solution. Biochemistry 27, 122-136.
26. Jouanneau, E., Alberti, L., Nejjari, M., Treilleux, I., Vilgrain, I., Duc, A., Combaret, V., Favrot, M., Leboulch, P., and Bachelot, T. (2001) Lack of antitumor activity of recombinant endostatin in a human neuroblastoma xenograft model. J. Neurooncol. 51, 11-18.
27. Eisterer, W., Jiang, X., Bachelot, T., Pawliuk, R., Abramovich, C., Leboulch, P., Hogge, D., and Eaves, C. (2002) Unfulfilled promise of endostatin in a gene therapy-xenotransplant model of human acute lymphocytic leukemia. Mol. Ther. 5, 352-359.
28. Pawliuk, R., Bachelot, T., Zurkiya, O., Eriksson, A., Cao, Y., and Leboulch, P. (2002) Continuous intravascular secretion of endostatin in mice from transduced hematopoietic stem cells. Mol. Ther. 5, 345-351.
29. Marshall, E. (2002) Setbacks for endostatin. Science 295, 2198-2199.
30. Tang, H., Fu, Y., Lei, Q., Han, Q., Ploplis, V. A., Castellino, F. J., Li, L., and Luo, Y. (2009) Fibrinogen facilitates the anti-tumor effect of nonnative endostatin. Biochem. Biophys. Res. Commun. 380, 249-253.
31. Tjin Tham Sjin, R. M., Satchi-Fainaro, R., Birsner, A. E., Ramanujam, V. M., Folkman, J., and Javaherian, K. (2005) A 27-amino-acid synthetic peptide corresponding to the NH2-terminal zinc-binding domain of endostatin is responsible for its antitumor activity. Cancer Res. 65, 3656-3663.
32. Margineanu, I. and Ghetic, V. (1981) A selective model of plasma protein catabolism. J. Theor. Biol. 90, 101-110.
33. Pluskota, E. and D'souza, S. E. (2000) Fibrinogen interactions with ICAM-1 (CD54) regulate endothelial cell survival. Eur. J. Biochem. 267, 4693-4704.
34. Suehiro, K., Mazuguchi, J., Nishiyama, K., Iwanaga, S., Farrell, D. H., and Ohtaki, S. (2000) Fibrinogen binds to integrin alpha(5)beta(1)via the carboxyl-terminal RGD site of the Aalpha-chain. J. Biochem. (Tokyo) 128, 705-710.
35. Rehn, M., Veikkola, T., Kukk-Valdre, E., Nakamura, H., Ilmonen, M., Lombardo, C., Pihlajaniemi, T., Alitalo, K., and Vuori, K. (2001) Interaction of endostatin with integrins implicated in angiogenesis. Proc. Natl. Acad. Sci. USA 98, 1024-1029.
36. Sudhakar, A., Sugimoto, H., Yang, C., Lively, J., Zeisberg, M., and Kalluri, R. (2003) Human tumstatin and human endostatin exhibit distinct antiangiogenic activities mediated by alpha v beta 3 and alpha 5 beta 1 integrins. Proc. Natl. Acad. Sci. USA 100, 4766-4771.
37. Oijen, M. V., Witteman, J. C., Hofman, A., Koudstaal, P. J., Breteler, M. M. B. (2005) Fibrinogen is associated with an increased risk of Alzheimer disease and vascular dementia. Stroke 36, 2637-2641.
38. Hohenester, E., Sasaki, T., Mann, K., and Timpl, R. (2000) Variable zinc coordination in endostatin. J. Mol. Biol. 297, 1-6.
39. Han, Q., Fu, Y., Zhou, H., He, Y., and Luo, Y. (2007) Contributions of Zn(II)-binding to the structural stability of endostatin. FEBS Lett. 581, 3027-3032.
40. Boehm, T., O'Reilly, M. S., Keough, K., Shiloach, J., Shapiro, R., and Folkman, J. (1998) Zinc-binding of endostatin is essential for its antiangiogenic activity. Biochem. Biophys. Res. Commun. 252, 190-194.
41. Sim, B. K., Fogler, W. E., Zhou, X. H., Liang, H., Madsen, J. W., Luu, K., O'Reilly, M. S., Tomaszewski, J. E., and Fortier, A. H. (1999) Zinc ligand-disrupted recombinant human endostatin: potent inhibition of tumor growth, safety and pharmacokinetic profile. Angiogenesis 3, 41-51.
42. Fu, Y., Gao, L., Huang, Y. J., Tang, H. D., Li, H. Y., Song, N. Shi, H. B., Chang, G. D. and Luo, Y. Z. (2009) Parallel comparison between N-terminal modified endostatin expressed in E. coli and wild type endostatin expressed in Pichia pastoris, Submitted.
43. Macpherson, G. R., Ng, S. S., Forbes, S. L., Melillo, G., Karpova, T., McNally, J., Conrads, T. P., Veenstra, T. D., Martinez, A., Cuttitta, F., Price, D. K., and Figg, W. D. (2003) Anti-angiogenic activity of human endostatin is HIF-1-independent in vitro and sensitive to timing of treatment in a human saphenous vein assay. Mol. Cancer Ther. 2, 845-854.
44. Schwartz, M. K. (1975) Role of trace elements in cancer. Cancer Res. 35, 3481-3487.
45. Ogunlewe, J. O. and Osegbe, D. N. (1989) Zinc and cadmium concentrations in indigenous blacks with normal, hypertrophic, and malignant prostate. Cancer 63, 1388-1392.
46. Becker, C. M., Sampson, D. A., Short, S. M., Javaherian, K., Folkman, J., and D'Amato, R. J. (2006) Short synthetic endostatin peptides inhibit endothelial migration in vitro and endometriosis in a mouse model. Fertil. Steril. 85, 71-77.
47. Celik, I., Surucu, O., Dietz, C., Heymach, J. V., Force, J., Hoschele, I., Becker, C. M., Folkman, J., and Kisker, O. (2005) Therapeutic efficacy of endostatin exhibits a biphasic dose-response curve. Cancer Res. 65, 11044-11050.
48. Ricard-Blum, S., Feraud, O., Lortat-Jacob, H., Rencurosi, A., Fukai, N., Dkhissi, F., Vittet, D., Imberty, A., Olsen, B. R., and van der Rest, M. (2004) Characterization of endostatin binding to heparin and heparan sulfate by surface plasmon resonance and molecular modeling: role of divalent cations. J. Biol. Chem. 279, 2927-2936.
49. Jia, H. and Kling, J. (2006) China offers alternative gateway for experimental drugs. Nat. Biotechnol. 24, 117-118.
50. Kulke, M. H., Bergsland, E. K., Ryan, D. P., Enzinger, P. C., Lynch, T. J., Zhu, A. X., Meyerhardt, J. A., Heymach, J. V., Fogler, W. E., Sidor, C., Michelini, A., Kinsella, K., Venook, A. P., and Fuchs, C. S. (2006) Phase II study of recombinant human endostatin in patients with advanced neuroendocrine tumors. J. Clin. Oncol. 24, 3555-3561.
51. Yang, L., Wang, J., Sun, Y., Zhu, Y., Liu, X., Li, W., Di, L., Li, P., Wang, Y., Song, S., Yao, C., and You, L. (2006) Randomized phase II trial on escalated doses of Rh-endostatin (YH-16) for advanced nonsmall cell lung cancer. Chin. J. Oncol. 28, 4.
52. Yang, L., Wang, J., Cui, C., Huang, J., Zhang, H., Li, S., and Sun, Y. (2005) Rh-endostatin (YH-16) in combination with vinorelbine and cisplatin for advanced non-small cell lung cancer: a multicenter phase II trial. Chin. J. New Drugs 14, 4.
53. Eder, J. P. Jr., Supko, J. G., Clark, J. W., Puchalski, T. A., Garcia-Carbonero, R., Ryan, D. P., Shulman, L. N., Proper, J., Kirvan, M., Rattner, B., Connors, S., Keogan, M. T., Janicek, M. J., Fogler, W. E., Schnipper, L., Kinchla, N., Sidor, C., Phillips, E., Folkman, J., and Kufe, D. W. (2002) Phase I clinical trial of recombinant human endostatin administered as a short intravenous infusion repeated daily. J. Clin. Oncol. 20, 3772-3784.
54. Herbst, R. S., Hess, K. R., Tran, H. T., Tseng, J. E., Mullani, N. A., Charnsangavej, C., Madden, T., Davis, D. W., McConkey, D. J., O'Reilly, M. S., Ellis, L. M., Pluda, J., Hong, W. K., and Abbruzzese, J. L. (2002) Phase I study of recombinant human endostatin in patients with advanced solid tumors. J. Clin. Oncol. 20, 3792-3803.
55. Herbst, R. S., Mullani, N. A., Davis, D. W., Hess, K. R., McConkey, D. J., Charnsangavej, C., O'Reilly, M. S., Kim, H. W., Baker, C., Roach, J., Ellis, L. M., Rashid, A., Pluda, J., Bucana, C., Madden, T. L., Tran, H. T., and Abbruzzese, J. L. (2002) Development of biologic markers of response and assessment of antiangiogenic activity in a clinical trial of human recombinant endostatin. J. Clin. Oncol. 20, 3804-3814.
56. Thomas, J. P., Arzoomanian, R. Z., Alberti, D., Marnocha, R., Lee, F., Friedl, A., Tutsch, K., Dresen, A., Geiger, P., Pluda, J., Fogler, W., Schiller, J. H., and Wilding, G. (2003) Phase I pharmacokinetic and pharmacodynamic study of recombinant human endostatin in patients with advanced solid tumors. J. Clin. Oncol. 21, 223-231.
57. Hansma, A. H., Broxterman, H. J., van der Horst, I., Yuana, Y., Boven, E., Giaccone, G., Pinedo, H. M., and Hoekman, K. (2005) Recombinant human endostatin administered as a 28-day continuous intravenous infusion, followed by daily subcutaneous injections: a phase I and pharmacokinetic study in patients with advanced cancer. Ann. Oncol. 16, 1695-1701.
58. Yang, L., Wang, J., Tang, Z., Liu, X., Huang, J., Li, S., Dong, Y., Zhang, H., Xue, L., Chu, D., and Sun, Y. (2004) A phase I clinical trial for recombinant human endostatin. Chin. J. New Drugs 13, 6.
59. Wang, J., Sun, Y., Liu, Y., Yu, Q., Zhang, Y., Li, K., and Zhu, Y. (2005) Results of randomized, multicenter, double-blind phase III trial of rh-endostatin (YH-16) in treatment of advanced non2small cell lung cancer patients. Chin. J. Lung Cancer 8, 8.
60. Kisker, O., Becker, C. M., Prox, D., Fannon, M., D'Amato, R., Flynn, E., Fogler, W. E., Sim, B. K., Allred, E. N., Pirie-Shepherd, S. R., and Folkman, J. (2001) Continuous administration of endostatin by intraperitoneally implanted osmotic pump improves the efficacy and potency of therapy in a mouse xenograft tumor model. Cancer Res. 61, 7669-7674.
61. Bergers, G., Javaherian, K., Lo, K. M., Folkman, J., and Hanahan, D. (1999) Effects of angiogenesis inhibitors on multistage carcinogenesis in mice. Science 284, 808-812.
62. Folkman, J. (2007) Endostatin finds a new partner: nucleolin. Blood 110, 2786-2787.
63. Whitworth, A. (2006) Endostatin: are we waiting for godot? J Natl Cancer Inst. 98, 731-733.
64. Abdollahi, A., Hlatky, L., and Huber, P. E. (2005) Endostatin: the logic of antiangiogenic therapy. Drug Resist. Updat. 8, 59-74.
65. Plum, S. M., Hanson, A. D., Volker, K. M., Vu, H. A., Sim, B. K. L., Fogler, W. E., and Fortier, A. H. (2003) Synergistic activity of recombinant human endostatin in combination with adriamycin: analysis of in vitro activity on endothelial cells and in vivo tumor progression in an orthotopic murine mammary carcinoma model. Clin. Cancer Res. 9, 4619-4626.
66. Hurwitz, H. (2004) Integrating the anti-VEGF-A humanized monoclonal antibody bevacizumab with chemotherapy in advanced colorectal cancer. Clin. Colorectal Cancer4 Suppl 2, S62-S68.
67. Hurwitz, H., Fehrenbacher, L., Novotny, W., Cartwright, T., Hainsworth, J., Heim, W., Berlin, J., Baron, A., Griffing, S., Holmgren, E., Ferrara, N., Fyfe, G., Rogers, B., Ross, R., and Kabbinavar, F. (2004) Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N. Engl. J. Med. 350, 2335-2342.
68. Gasparini, G., Longo, R., Fanelli, M., and Teicher, B. A. (2005) Combination of antiangiogenic therapy with other anticancer therapies: results, challenges, and open questions. J. Clin. Oncol. 23, 1295-1311.
69. Folkman, J. (2006) Antiangiogenesis in cancer therapy - endostatin and its mechanisms of action. Exp. Cell Res. 312, 594-607.
70. Javaherian, K., Park, S. Y., Pickl, W. F., LaMontagne, K. R., Sjin, R. T., Gillies, S., and Lo, K. M. (2002) Laminin modulates morphogenic properties of the collagen XVIII endostatin domain. J. Biol. Chem. 277, 45211-45218.
71. Karumanchi, S. A., Jha, V., Ramchandran, R., Karihaloo, A., Tsiokas, L., Chan, B., Dhanabal, M., Hanai, J. I., Venkataraman, G., Shriver, Z., Keiser, N., Kalluri, R., Zeng, H., Mukhopadhyay, D., Chen, R. L., Lander, A. D., Hagihara, K., Yamaguchi, Y., Sasisekharan, R., Cantley, L., and Sukhatme, V. P. (2001) Cell surface glypicans are low-affinity endostatin receptors. Mol. Cell 7, 811-822.
72. Lee, S. J., Jang, J. W., Kim, Y. M., Lee, H. I., Jeon, J. Y., Kwon, Y. G., and Lee, S. T. (2002) Endostatin binds to the catalytic domain of matrix metalloproteinase-2. FEBS Lett. 519, 147-152.
73. MacDonald, N. J., Shivers, W. Y., Narum, D. L., Plum, S. M., Wingard, J. N., Fuhrmann, S. R., Liang, H., Holland-Linn, J., Chen, D. H., and Sim, B. K. (2001) Endostatin binds tropomyosin. A potential modulator of the antitumor activity of endostatin. J. Biol. Chem. 276, 25190-25196.
74. Kim, Y. M., Hwang, S., Kim, Y. M., Pyun, B. J., Kim, T. Y., Lee, S. T., Gho, Y. S., and Kwon, Y. G. (2002) Endostatin blocks vascular endothelial growth factor-mediated signaling via direct interaction with KDR/Flk-1. J. Biol. Chem. 277, 27872-27879.
75. Drenckhahn, D. and Mannherz, H. G. (1983) Distribution of actin and the actin-associated proteins myosin, tropomyosin, alpha-actinin, vinculin, and villin in rat and bovine exocrine glands. Eur. J. Cell Biol. 30, 167-176.
76. Perry, S. V. (2001) Vertebrate tropomyosin: distribution, properties and function. J. Muscle Res. Cell Motil. 22, 5-49.
77. Egeblad, M. and Werb, Z. (2002) New functions for the matrix metalloproteinases in cancer progression. Nat. Rev. Cancer 2, 161-174.
78. Coussens, L. M., Fingleton, B., and Matrisian, L. M. (2002) Matrix metalloproteinase inhibitors and cancer: trials and tribulations. Science 295, 2387-2392.
79. Kim, Y. M., Jang, J. W., Lee, O. H., Yeon, J., Choi, E. Y., Kim, K. W., Lee, S. T., and Kwon, Y. G. (2000) Endostatin inhibits endothelial and tumor cellular invasion by blocking the activation and catalytic activity of matrix metalloproteinase. Cancer Res. 60, 5410-5413.
80. Yu, Y., Moulton, K. S., Khan, M. K., Vineberg, S., Boye, E., Davis, V. M., O'Donnell, P. E., Bischoff, J., and Milstone, D. S. (2004) E-selectin is required for the antiangiogenic activity of endostatin. Proc. Natl. Acad. Sci. USA 101, 8005-8010.
81. Sasaki, T., Larsson, H., Kreuger, J., Salmivirta, M., Claesson-Welsh, L., Lindahl, U., Hohenester, E., and Timpl, R. (1999) Structural basis and potential role of heparin/heparan sulfate binding to the angiogenesis inhibitor endostatin. EMBO J. 18, 6240-6248.
82. Carey, D. J., Stahl, R. C., Asundi, V. K., and Tucker, B. (1993) Processing and subcellular distribution of the Schwann cell lipid-anchored heparan sulfate proteoglycan and identification as glypican. Exp. Cell Res. 208, 10-18.
83. Ginisty, H., Sicard, H., Roger, B., and Bouvet, P. (1999) Structure and functions of nucleolin. J. Cell Sci. 112(Part 6), 761-772.
84. Ginisty, H., Amalric, F., and Bouvet, P. (1998) Nucleolin functions in the first step of ribosomal RNA processing. EMBO J. 17, 1476-1486.
85. Erard, M. S., Belenguer, P., Caizergues-Ferrer, M., Pantaloni, A., and Amalric, F. (1988) A major nucleolar protein, nucleolin, induces chromatin decondensation by binding to histone H1. Eur. J. Biochem. 175, 525-530.
86. Kharrat, A., Derancourt, J., Doree, M., Amalric, F., and Erard, M. (1991) Synergistic effect of histone H1 and nucleolin on chromatin condensation in mitosis: role of a phosphorylated heteromer. Biochemistry 30, 10329-10336.
87. Christian, S., Pilch, J., Akerman, M. E., Porkka, K., Laakkonen, P., and Ruoslahti, E. (2003) Nucleolin expressed at the cell surface is a marker of endothelial cells in angiogenic blood vessels. J. Cell Biol. 163, 871-878.
88. Huang, Y., Shi, H., Zhou, H., Song, X., Yuan, S., and Luo, Y. (2006) The angiogenic function of nucleolin is mediated by vascular endothelial growth factor and nonmuscle myosin. Blood 107, 3564-3571.
89. Abdollahi, A., Hahnfeldt, P., Maercker, C., Grone, H. J., Debus, J., Ansorge, W., Folkman, J., Hlatky, L., and Huber, P. E. (2004) Endostatin's antiangiogenic signaling network. Mol. Cell 13, 649-663.
90. Folkman, J. (2007) Angiogenesis: an organizing principle for drug discovery? Nat. Rev. Drug Discov. 6, 273-286.
91. Kebebew, E., Peng, M., Treseler, P. A., Clark, O. H., Duh, Q. Y., Ginzinger, D., and Miner, R. (2004) Id1 gene expression is up-regulated in hyperplastic and neoplastic thyroid tissue and regulates growth and differentiation in thyroid cancer cells. J. Clin. Endocrinol. Metab. 89, 6105-6111.
92. Pammer, J., Reinisch, C., Kaun, C., Tschachler, E., and Wojta, J. (2004) Inhibitors of differentiation/DNA binding proteins Id1 and Id3 are regulated by statins in endothelial cells. Endothelium 11, 175-180.
93. Hara, E., Yamaguchi, T., Nojima, H., Ide, T., Campisi, J., Okayama, H., and Oda, K. (1994) Id-related genes encoding helix-loop-helix proteins are required for G1 progression and are repressed in senescent human fibroblasts. J. Biol. Chem. 269, 2139-2145.
94. Yuan, S., Fu, Y., Wang, X., Shi, H., Huang, Y., Song, X., Li, L., Song, N., and Luo, Y. (2008) Voltage-dependent anion channel 1 is involved in endostatin-induced endothelial cell apoptosis. FASEB J. 22, 2809-2820.